Clinical trials: Staphylococcus Aureus Bacteremia
Bacteremia
Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives
Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform, two…
- Trial name
- NCT01184339
- Testing
- MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
- Volunteers
- 1,165 people
- Sponsor
- MicroPhage, Inc.
Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder)
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia…
- Conditions
- Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
- Trial name
- ERASE (NCT05329168)
- Testing
- Tonabacase (LSVT-1701)
- Where
- United States
- Sponsor
- Lysovant
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Network Adaptive Platform Trial
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with…
- Trial name
- SNAP (NCT05137119)
- Testing
- Cefazolin, Penicillin, Clindamycin
- Where
- 161 sites in United States, Australia and 11 more
- Volunteers
- 8,000 people
- Sponsor
- University of Melbourne
Staphylococcus Aureus Bacteremia
Evaluating Simplified Layered Consent for Clinical Trials
The goal of this clinical trial (the SIMPLY-SNAP trial) is to compare a simplified layered consent form to a full-length consent form for use during the informed consent process for a larger clinical trial of treatment of…
- Trial name
- SIMPLY-SNAP (NCT06168474)
- Testing
- Simplified layered consent form, Full-length consent form
- Where
- 6 sites in Canada
- Volunteers
- 347 people
- Sponsor
- Sunnybrook Health Sciences Centre
Bacteremia
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality.
- Trial name
- NCT02660346
- Testing
- Daptomycin, Vancomycin, Ceftaroline
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sharp HealthCare
Staphylococcus Aureus Infection
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia
The treatment of Methicillin-sensitive Staphylococcus aureus bacteremia is based on the first-line use of cefazolin or M penicillins (oxacillin and cloxacillin).
- Trial name
- DOSESACLOXA (NCT06495697)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 …
- Conditions
- Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
- Trial name
- RENSE (NCT01104662)
- Testing
- Vancomycin, Daptomycin, Semi-Synthetic Penicillin
- Where
- 10 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Infections
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main objective of this study will be to test the safety and behavior of Altastaph in patients with S.aureus bacteremia and continuing fever
- Trial name
- NCT00063089
- Testing
- S. aureus Immune Globulin Intravenous (Human) 5%
- Volunteers
- 40 people
- Sponsor
- Nabi Biopharmaceuticals
Bacteremia
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.
- Trial name
- NCT00505258
- Testing
- ceftobiprole medocaril
- Sponsor
- Basilea Pharmaceutica
Staphylococcal Bacteraemia
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with…
- Trial name
- NCT04775953
- Testing
- Cefazolin, Dalbavancin, Daptomycin
- Where
- 24 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S.
- Trial name
- SABOT (NCT06249451)
- Testing
- Checklist-based phone calls
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University Medicine Greifswald
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staph Aureus Methicillin Resistant Bacteremia
Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.
- Trial name
- NCT01898338
- Testing
- Fosfomycin 2gr/6h iv, Daptomycin 10mg/kg/24h iv
- Where
- 18 sites in Spain
- Volunteers
- 167 people
- Sponsor
- Miquel Pujol
Staphylococcus Aureus, Staphylococcal Skin Infections
Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections
The purpose of this study is to determine whether the Cepheid GeneXpert system accurately detects Methicillin-Resistant and -Susceptible Staphylococcus aureus in blood cultures and wound swabs.
- Conditions
- Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
- Trial name
- NCT01198262
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Infection, Bacteremia
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied.
- Trial name
- NCT01321879
- Testing
- Telavancin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Bacteremia
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).
- Trial name
- NCT01728376
- Testing
- Daptomycin, Comparator
- Volunteers
- 82 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteraemia
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S.
- Trial name
- NCT01911624
- Testing
- direct thrombin inhibition, enoxaparin
- Where
- Belgium
- Volunteers
- 94 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Nosocomial Infection, Healthcare-associated Infection
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose blood cultures are sterilized after 72 hours…
- Trial name
- DAVASAB (NCT01515020)
- Testing
- vancomycin monotherapy, daptomycin monotherapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.
- Trial name
- NCT02439359
- Testing
- CF-301
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ContraFect